Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to

Ying Zhang1, Francesca Garofano1, Xiaolong Wu1

  • 1Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Venusberg-Campus 1, D-53127, Bonn, Germany.

Insights

This study identifies key genes and pathways involved in thyroid dysfunction caused by anti-CTLA-4 cancer therapy. Findings may aid in diagnosing and managing immune-related adverse events in patients.

Area of Science:

  • Immunology
  • Oncology
  • Endocrinology

Background:

  • Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors are effective cancer treatments.
  • Immune-related adverse events (IRAEs), such as autoimmune thyroid dysfunction, can limit CTLA-4 therapy.
  • Identifying mechanisms of IRAEs is crucial for patient management.

Purpose of the Study:

  • To investigate candidate genes and signaling pathways in anti-CTLA-4 therapy-induced autoimmune thyroid dysfunction.
  • To identify potential biomarkers for early diagnosis and management of these IRAEs.

Main Methods:

  • Integrated analysis of Gene Expression Omnibus (GEO) datasets and text mining to identify differentially expressed genes (DEGs).
  • Functional enrichment analysis using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.
  • Protein-protein interaction (PPI) network construction and hub gene identification using STRING and Cytoscape.

Main Results:

  • Identified 22 DEGs in hypothyroidism and 17 DEGs in hyperthyroidism related to anti-CTLA-4 therapy.
  • Discovered significant GO terms and KEGG pathways for both hypothyroid and hyperthyroid groups.
  • Pinpointed top hub genes for hypothyroidism (ALB, MAPK1, SPP1, PPARG, MIF) and hyperthyroidism (ALB, FCGR2B, CD44, LCN2, CD74).

Conclusions:

  • The identified genes and pathways offer potential biomarkers for anti-CTLA-4 therapy-induced autoimmune thyroid dysfunction.
  • These findings may improve the diagnosis and management of IRAEs in cancer patients undergoing CTLA-4 treatment.